Skip to content

Effect of Lavender capsules in Chronic rhinosinusitis

The effect of traditional medicinal composition based on Lavender in Chronic rhinosinusitis

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20171028037044N6
Enrollment
56
Registered
2025-02-21
Start date
2025-02-19
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic rhinosinusitis. Chronic sinusitis, unspecified

Interventions

Intervention 1: Intervention group: Standard treatment and lavender capsules will be given, one after lunch and one after dinner. This capsule, which contains the main composition of lavender and its

Sponsors

Mazandaran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Symptoms of chronic sinusitis lasting more than 12 weeks Diagnosis of chronic rhinosinusitis based on EPOS (2012) criteria, requiring at least two major criteria or one major criterion and two minor criteria.

Exclusion criteria

Exclusion criteria: Use of topical corticosteroids within 15 days prior to enrollment Use of antibiotics within 15 days prior to enrollment Use of oral corticosteroids within 30 days prior to enrollment Multiple nasal polyps History of nasal or sinus surgery within the last 5 years Moderate to severe asthma or mild asthma with an acute exacerbation in the past 30 days Drug-induced rhinitis Known hypersensitivity to herbal medicines or excipients Symptoms and signs of bacterial sinusitis (fever =38.5°C, orbital complications, severe unilateral frontal pain, or dental pain) Acute fungal sinusitis Acute seasonal allergy Underlying Diseases like Cystic fibrosis, cardiac, renal, pulmonary, or hepatic failure, Neurological or psychiatric disorders, Substance or alcohol abuse, Malignancies or immunodeficiencies Pregnancy Breastfeeding

Design outcomes

Primary

MeasureTime frame
Improvement of symptoms based on SNOT-22. Timepoint: Before intervention (day 0), and end of intervention (day 28). Method of measurement: SNOT-22 Questionnaire.

Secondary

MeasureTime frame
Side effects. Timepoint: Day 7; day 28. Method of measurement: Ask the patient; The patient stated.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyde Sedighe Yousefi

Mazandaran University of Medical Sciences

s.yousefi@mazums.ac.ir+98 11 3324 4893

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026